- Home
- LIDR vs EVAX Comparison
LIDR vs EVAX Comparison
Compare LIDR & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIDR
- EVAX
- Stock Information
- Founded
- LIDR 2013
- EVAX 2008
- Country
- LIDR United States
- EVAX Denmark
- Employees
- LIDR N/A
- EVAX N/A
- Industry
- LIDR Auto Parts:O.E.M.
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LIDR Consumer Discretionary
- EVAX Health Care
- Exchange
- LIDR Nasdaq
- EVAX Nasdaq
- Market Cap
- LIDR 9.8M
- EVAX 16.3M
- IPO Year
- LIDR N/A
- EVAX 2021
- Fundamental
- Price
- LIDR $0.56
- EVAX $1.83
- Analyst Decision
- LIDR Hold
- EVAX Strong Buy
- Analyst Count
- LIDR 1
- EVAX 3
- Target Price
- LIDR N/A
- EVAX $33.33
- AVG Volume (30 Days)
- LIDR 657.7K
- EVAX 258.4K
- Earning Date
- LIDR 02-20-2025
- EVAX 03-26-2025
- Dividend Yield
- LIDR N/A
- EVAX N/A
- EPS Growth
- LIDR N/A
- EVAX N/A
- EPS
- LIDR N/A
- EVAX N/A
- Revenue
- LIDR $202,000.00
- EVAX $3,295,000.00
- Revenue This Year
- LIDR $2,677.23
- EVAX $9,039.73
- Revenue Next Year
- LIDR $409.09
- EVAX $1.47
- P/E Ratio
- LIDR N/A
- EVAX N/A
- Revenue Growth
- LIDR N/A
- EVAX N/A
- 52 Week Low
- LIDR $0.51
- EVAX $1.70
- 52 Week High
- LIDR $5.15
- EVAX $22.05
- Technical
- Relative Strength Index (RSI)
- LIDR 35.02
- EVAX 34.89
- Support Level
- LIDR $0.51
- EVAX $1.75
- Resistance Level
- LIDR $0.66
- EVAX $1.99
- Average True Range (ATR)
- LIDR 0.09
- EVAX 0.18
- MACD
- LIDR 0.01
- EVAX 0.03
- Stochastic Oscillator
- LIDR 14.09
- EVAX 13.13
About LIDR AEye Inc.
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.